Table 2.
Characterization of the study group.
| Adalimumab | Etanercept | Infliksymab | All patients | Control | |
|---|---|---|---|---|---|
| n | 19 (7 K, 12 M) | 11 (5F, 6 M) | 7 (5F, 2 M) | 37 (17 K, 20 M) | 30 (11F, 19 M) |
| Age (years) (Mean ± SEM) | 48.6 ± 13.4 | 50.6 ± 11.5 | 49.9 ± 12.5 | 49.7 ± 12.5 | 45.4 ± 10.1 |
| Psoriasis duration (years) (Mean ± SEM) | 19.1 ± 11.2 | 18.0 ± 13.2 | 23.3 ± 13.4 | 20,1 ± 12.6 | – |
| BMI (kg/m2) (Mean ± SEM) | 28.7 ± 0.9 | 28.0 ± 3.0 | 28.1 ± 3.2 | 28.3 ± 2.4 | 24.41 ± 0.87 |
| Psoriatic arthritis n (%) | 6 (31.6) | 9 (81.8) | 4 (57.1) | 19 (51.3) | – |
| Hypertension n (%) | 10 (52.6) | 5 (45.5) | 4 (57.1) | 19 (51.4) | 8 (26.6) |
| Ischemic heart disease n (%) | 3 (15.8) | 1 (9.1) | 1 (14.3) | 5 (13.5) | 2 (6.7) |
| History of acute coronary syndrome n (%) | 1 (5.2) | 0 | 0 | 1 (2.7) | 0 |
| Type 2 diabetes n (%) | 1 (5.2) | 1 (9.1) | 0 | 2 (5.4) | 1 (3.3) |
| Glaucoma n (%) | 1 (5.2) | 1 (9.1) | 0 | 2 (5.4) | 0 |
| Cigarette smoking n (%) | 7 (36.8) | 5 (45.5) | 2 (28.6) | 14 (37.8) | 3 (10) |
| Obesity n (%) | 7 (36.8) | 4 (36.4) | 3 (42.9) | 14 (37.8) | 5 (16.7) |
| Crohn's disease n (%) | 0 | 0 | 1 (14.3) | 1 (2.7) | 0 |
| Hyperthyroidism n (%) | 0 | 0 | 0 | 1 (2.7) | 1 (3.3) |
| Peripheral artery disease n (%) | 1 (5.2) | 1 (9.1) | 0 | 2 (5.4) | 0 |